Thalidomide Selectively Inhibits Tumor Necrosis Factor Alpha Production by Stimulated Human Monocytes

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 1991 Mar 1

PMID 1997652

Citations 247

Authors

E P Sampaio

E N Sarno

R Galilly

Z A COHN

G Kaplan

Affiliations

Soon will be listed here.

Abstract

Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor alpha (TNF-alpha) when these cells are triggered with lipopolysaccharide and other agonists in culture. 40% inhibition occurs at the clinically achievable dose of the drug of 1 micrograms/ml. In contrast, the amount of total protein and individual proteins labeled with [35S]methionine and expressed on SDS-PAGE are not influenced. The amounts of interleukin 1 beta (IL-1 beta), IL-6, and granulocyte/macrophage colony-stimulating factor produced by monocytes remain unaltered. The selectivity of this drug may be useful in determining the role of TNF-alpha in vivo and modulating its toxic effects in a clinical setting.

Citing Articles

Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma.

Karimi F, Aghaei M, Saki N Curr Treat Options Oncol. 2025; .

PMID: 40042740 DOI: 10.1007/s11864-025-01295-8.

Kaposi's sarcoma unmasked by corticosteroids in an advanced HIV patient with tuberculosis immune reconstitution inflammatory syndrome.

Kadnur H, Reddy H, Wanve B, Sonowal R, Rughwani H, Sekaran A Indian J Sex Transm Dis AIDS. 2025; 45(2):141-143.

PMID: 39886252 PMC: 11776919. DOI: 10.4103/ijstd.ijstd_8_24.

Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.

Villegas-Vazquez E, Marin-Carrasco F, Reyes-Hernandez O, Baez-Gonzalez A, Bustamante-Montes L, Padilla-Benavides T Front Oncol. 2025; 14:1514120.

PMID: 39876896 PMC: 11772297. DOI: 10.3389/fonc.2024.1514120.

Asymmetric Dirhodium-Catalyzed Modification of Immunomodulatory Imide Drugs and Their Biological Assessment.

Tracy W, Davies G, Jia L, Evans E, Sun Z, Buenviaje J ACS Med Chem Lett. 2024; 15(9):1575-1583.

PMID: 39291008 PMC: 11403733. DOI: 10.1021/acsmedchemlett.4c00297.

Tumor Necrosis Factor-Alpha: Ally and Enemy in Protean Cutaneous Sceneries.

Pocino K, Carnazzo V, Stefanile A, Basile V, Guerriero C, Marino M Int J Mol Sci. 2024; 25(14).

PMID: 39063004 PMC: 11276697. DOI: 10.3390/ijms25147762.

References

RIDLEY D . Reactions in leprosy. Lepr Rev. 1969; 40(2):77-81. DOI: 10.5935/0305-7518.19690016. View

MELLIN G, KATZENSTEIN M . The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med. 1962; 267:1184-92 contd. DOI: 10.1056/NEJM196212062672305. View

Landegren U . Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. J Immunol Methods. 1984; 67(2):379-88. DOI: 10.1016/0022-1759(84)90477-0. View

Moncada B, Baranda M, Gonzalez-Amaro R, Urbina R, Loredo C . Thalidomide--effect on T cell subsets as a possible mechanism of action. Int J Lepr Other Mycobact Dis. 1985; 53(2):201-5. View

Wallis R, Fujiwara H, Ellner J . Direct stimulation of monocyte release of interleukin 1 by mycobacterial protein antigens. J Immunol. 1986; 136(1):193-6. View

Beutler B, Krochin N, Milsark I, Luedke C, Cerami A . Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science. 1986; 232(4753):977-80. DOI: 10.1126/science.3754653. View

Scuderi P, Sterling K, Lam K, FINLEY P, Ryan K, RAY C . Raised serum levels of tumour necrosis factor in parasitic infections. Lancet. 1986; 2(8520):1364-5. DOI: 10.1016/s0140-6736(86)92007-6. View

Finkelman F, Katona I, Urban Jr J, Snapper C, OHara J, Paul W . Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1. Proc Natl Acad Sci U S A. 1986; 83(24):9675-8. PMC: 387203. DOI: 10.1073/pnas.83.24.9675. View

Oliff A, Boyer M, Martinez D, Kiefer D, Vuocolo G, Wolfe A . Tumors secreting human TNF/cachectin induce cachexia in mice. Cell. 1987; 50(4):555-63. DOI: 10.1016/0092-8674(87)90028-6. View

10.

Balkwill F, Osborne R, Burke F, Naylor S, Talbot D, Durbin H . Evidence for tumour necrosis factor/cachectin production in cancer. Lancet. 1987; 2(8570):1229-32. DOI: 10.1016/s0140-6736(87)91850-2. View

11.

Tracey K, Wei H, Manogue K, Fong Y, Hesse D, Nguyen H . Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med. 1988; 167(3):1211-27. PMC: 2188883. DOI: 10.1084/jem.167.3.1211. View

12.

Girardin E, Grau G, Dayer J, Roux-Lombard P, Lambert P . Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med. 1988; 319(7):397-400. DOI: 10.1056/NEJM198808183190703. View

13.

Lahdevirta J, Maury C, Teppo A, Repo H . Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med. 1988; 85(3):289-91. DOI: 10.1016/0002-9343(88)90576-1. View

14.

Bursten S, Locksley R, Ryan J, Lovett D . Acylation of monocyte and glomerular mesangial cell proteins. Myristyl acylation of the interleukin 1 precursors. J Clin Invest. 1988; 82(5):1479-88. PMC: 442712. DOI: 10.1172/JCI113755. View

15.

Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T . The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med. 1989; 169(1):333-8. PMC: 2189201. DOI: 10.1084/jem.169.1.333. View

16.

Navarro S, Debili N, Bernaudin J, Vainchenker W, DOLY J . Regulation of the expression of IL-6 in human monocytes. J Immunol. 1989; 142(12):4339-45. View

17.

Havell E . Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol. 1989; 143(9):2894-9. View

18.

Wallis R, Ellner J . Induction of interleukin 1 and tumor necrosis factor by mycobacterial proteins: the monocyte western blot. Proc Natl Acad Sci U S A. 1990; 87(9):3348-52. PMC: 53897. DOI: 10.1073/pnas.87.9.3348. View

19.

Barnes P, Fong S, Brennan P, Twomey P, Mazumder A, Modlin R . Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis. J Immunol. 1990; 145(1):149-54. View

20.

Barnhill R, McDOUGALL A . Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J Am Acad Dermatol. 1982; 7(3):317-23. DOI: 10.1016/s0190-9622(82)70118-5. View